Recent Updates
Recently added Catalysts

Ascentage Pharma HQP1351 bioavailable inhibitor

Phase 1

Leukemia, Myeloid, Chronic | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Nov 5, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLED
Total Trials1
Total Enrollment242
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04260022Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLPHASE1 RECRUITING 242 — — Jan 9, 2020Mar 31, 2030Nov 5, 20259 United States, United States +7
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
Ascentage Pharma HQP1351 bioavailable inhibitorDRUGHQP1351 taken by mouth every other day
BlinatumomabDRUGAdministered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT04260022studyFirstPostDate: changed